Genetically modified NK cells take on rare sarcomas in early trial
NCT ID NCT06083883
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This early-phase trial tests a new therapy for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. Participants receive donated natural killer (NK) cells that have been engineered to recognize and attack a protein called NY-ESO-1 found on their cancer cells. These cells are given alongside two chemotherapy drugs to help them work better. The study aims to find the safest dose and check for side effects in 44 patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- engineered natural killer (NK) cells that target the NY-ESO-1 protein, given with chemotherapy drugs fludarabine and cyclophosphamide
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced synovial sarcoma or liposarcoma that has not responded to other therapies.
- What could go wrong
- This is a very early (Phase 1) trial with only 44 participants, so the main goal is safety, not effectiveness. The treatment may not shrink tumors or could cause serious side effects from the chemotherapy or the cell infusion.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYXOID/ROUND CELL LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a genetic marker guide future cancer therapies in taiwan?
- New immunotherapy targets rare cancers by harnessing the Body's immune system
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New pill may keep soft tissue sarcoma in check after chemo
- New registry aims to unlock secrets of rare sarcoma
- Glow-in-the-Dark dye could help surgeons find hidden lung cancer in teens